Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

HemaCare Supports Cell & Gene Meeting on the Mesa

HemaCare Corporation
Posted on: 26 Sep 16

HemaCare Corporation (OTCBB:HEMA), a leader in cell and tissue collection, processing, and cell therapy solutions, today announced that it is supporting the 2016 Cell and Gene Meeting on the Mesa to be held at the Estancia Hotel and the Salk Institute in La Jolla, October 5th-7th. This meeting is organized by the Alliance for Regenerative Medicine in partnership with the Sanford Consortium for Regenerative Medicine and is the premier annual meeting, bringing together over 800 cell therapy key opinion leaders, scientific researchers from academia and industry, industry decision-makers, clinical leaders and patient advocates. The focus of this meeting is to collaborate on the development and clinical trial testing of therapies utilizing various cell and gene-modification technologies to advance the delivery of these therapies to patients for the treatment of a wide range of diseases.

HemaCare is the recognized apheresis leader in supporting autologous and allogeneic cell therapy, as well as supplying a broad array of hematopoietic tissue–derived cells for research, including bone marrow and umbilical cord blood. What sets us apart from others is our heritage as a transfusable collection center with over 38 years of experience operating an FDA-registered, cGMP/cGTP compliant donor center. HemaCare manages hundreds of reliable & recallable donors, who can meet various criteria for selection to be used for allogeneic cell therapy starting material globally.

“We are enthusiastically sponsoring the Cell and Gene on the Mesa meeting to continue our commitment to participation in the discovery, development and delivery of critical therapies that involve the modification of genes and cells to treat disease,” said Pete van der Wal, HemaCare’s Chief Executive Officer. “HemaCare is devoted to supporting the advancement of these life-changing treatments with its comprehensive offering of human primary cells, in addition to our flexible and customizable solutions to meet the needs of these researchers.

View our product story at

About HemaCare

Since 1978, HemaCare Bioresearch Products & Services has been the trusted research partner of choice from concept to commercialization. Built on a 38-year history in apheresis collection, HemaCare is a leader in Cell and Tissue Collection, providing the high-quality biological material needed to ensure quality research outcomes that meet the unique needs of the scientific community. HemaCare’s expertise extends to serving biopharmaceutical firms with autologous and allogeneic collections used for Cell Therapy research, process development, and clinical trials. For more information please visit

View source version on

Business Wire

Last updated on: 26/09/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.